Sen. Sanders launch­es probe of Novo's We­govy and Ozem­pic pric­ing

Sen. Bernie Sanders (I-VT) is ramp­ing up his cam­paign against what he says are “out­ra­geous­ly high” list prices for No­vo Nordisk’s weight loss and di­a­betes block­busters We­govy and Ozem­pic.

The sen­a­tor an­nounced Wednes­day that his Com­mit­tee on Health, Ed­u­ca­tion, La­bor and Pen­sions (HELP) is launch­ing an in­ves­ti­ga­tion in­to No­vo’s pric­ing strat­e­gy, not­ing that We­govy and Ozem­pic are hun­dreds of dol­lars cheap­er in oth­er coun­tries. Sanders said in a let­ter to No­vo Nordisk CEO Lars Fruer­gaard Jør­gensen that high costs keep the drugs out of reach for some pa­tients, and threat­en to “bank­rupt Medicare, Med­ic­aid, and our en­tire health care sys­tem.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER